Αποτελέσματα Αναζήτησης
26 Ιουν 2018 · Of the 35 patients with recurrent WHO grade IV malignant glioma who were treated more than 24 months before March 20, 2018, a total of 8 patients remained alive as of that cutoff date. Two ...
26 Ιουν 2018 · A genetically modified poliovirus therapy developed at Duke Cancer Institute shows significantly improved long-term survival for patients with recurrent glioblastoma, with a three-year survival rate of 21 percent in a phase 1 clinical trial.
24 Ιουν 2021 · Evidence indicates these agents – oncolytic polio/rhinovirus recombinant (known as PVSRIPO) and pembrolizumab (marketed under the name Keytruda) – can work together to catalyze the immune system’s cancer-fighting response.
10 Φεβ 2020 · The Phase I trial, conducted at The Preston Robert Tisch Brain Tumor Center at Duke Cancer Institute, showed encouraging results. Overall survival among patients who received PVSRIPO plateaued at 21 percent at 24 to 36 months and appears to last for up to five years.
30 Ιαν 2020 · DURHAM, N.C. -- A modified form of poliovirus, pioneered at Duke Cancer Institute as a therapy for glioblastoma brain tumors, appears in laboratory studies to also have applicability for pediatric brain tumors when used as part of a cancer vaccine.
27 Ιαν 2020 · A new clinical trial is looking into validating whether a modified version of the virus that causes polio can impact the survival rates of people with glioblastoma (GBM), a deadly cancer of the brain.
8 Μαρ 2024 · To boost the immune system’s response, researchers at the NCI Center for Cancer Research’s Neuro-Oncology Branch (NOB) have created a cancer vaccine that can activate immune cells to recognize and attack glioblastomas.
